The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of *Prox1* expression in lymphatic endothelial cells

R. Sathish Srinivasan,¹ Xin Geng,¹ Ying Yang,¹ Yingdi Wang,¹ Suraj Mukatira,² Michèle Studer,³ Marianna P.R. Porto,¹ Oleg Lagutin,¹ and Guillermo Oliver^{1,4}

¹Department of Genetics and Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA;

²Hartwell Center for Bioinformatics and Biotechnology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA;

³Developmental Disorders Program, Telethon Institute of Genetics and Medicine, 80131 Napoli, Italy

The homeobox gene *Prox1* is crucial for mammalian lymphatic vascular development. In the absence of *Prox1*, lymphatic endothelial cells (LECs) are not specified. The maintenance of LEC identity also requires the constant expression of *Prox1*. However, the mechanisms controlling the expression of this gene in LECs remain poorly understood. The SRY-related gene *Sox18* is required to induce *Prox1* expression in venous LEC progenitors. Although *Sox18* is also expressed in embryonic arteries, these vessels do not express *Prox1*, nor do they give rise to LECs. This finding suggests that some venous endothelial cell-specific factor is required for the activation of *Prox1*. Here we demonstrate that the nuclear hormone receptor Coup-TFII is necessary for the activation of *Prox1* in embryonic veins by directly binding a conserved DNA domain in the regulatory region of *Prox1*. In addition, we show that the direct interaction between nuclear hormone receptors and *Prox1* is also necessary for the maintenance of *Prox1* expression during early stages of LEC specification and differentiation.

[**Keywords:** Lymphatics; *Prox1*; Coup-TFII; mouse; endothelial cell]

Supplemental material is available at <http://www.genesdev.org>.

Received August 31, 2009; revised version accepted February 18, 2010.

Because of differences in oncotic pressure, water, plasma, and other molecules continually escape from blood vessels. White blood cells also actively exit the blood vessels to take part in immune surveillance. One of the main functions of the lymphatic vasculature is to return these extravasated cells and molecules to the blood circulation.

Work performed during the last decade identified a number of key players required for the development of the mammalian lymphatic vasculature (Oliver and Alitalo 2005; Oliver and Srinivasan 2008), and determined that lymphatic endothelial cells (LECs) originate from embryonic veins (Srinivasan et al. 2007). One key player in the process of lymphatic vasculature formation is the homeobox gene *Prox1*. In mice, starting at around embryonic day 9.75 (E9.75), the expression of *Prox1* is detected in a subpopulation of endothelial cells (ECs) in the embryonic veins that will eventually acquire an LEC

phenotype (Wigle and Oliver 1999; Wigle et al. 2002; Srinivasan et al. 2007). As development progresses, the specified LECs migrate from the veins and form the primitive lymph sacs from which the entire lymphatic vasculature is eventually derived. In *Prox1*-null embryos, LEC specification does not take place; therefore, mutant embryos are devoid of a lymphatic vasculature (Wigle and Oliver 1999). Furthermore, conditional inactivation of *Prox1* during embryonic or postnatal stages is sufficient to dedifferentiate LECs back into blood ECs (Johnson et al. 2008).

Recent work identified the SRY-related HMG domain transcription factor *Sox18* as an upstream regulator of *Prox1* expression in venous LEC progenitors (Francois et al. 2008). In *Sox18*-null embryos, *Prox1* expression is not induced in venous ECs; therefore, LEC specification does not occur, and the formation of the lymphatic vasculature is arrested (Francois et al. 2008). *Sox18* expression is maintained in differentiating LECs and in forming lymphatic vessels up to around E14.5 (Francois et al. 2008). Interestingly, *Sox18* is expressed endogenously not only in venous ECs that subsequently differentiate into LECs, but also in arterial ECs (Pennisi et al.

⁴Corresponding author.

E-MAIL guillermo.oliver@stjude.org; FAX (901) 595-6035.

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.1859310>.

2000); however, in the latter cells, Sox18 expression is not sufficient to promote *Prox1* expression, and therefore LEC specification. This argues that, in veins, some other as-yet-unknown factor cooperates with Sox18 during the induction of *Prox1*, and a likely candidate for this role is the orphan nuclear receptor Coup-TFII.

Because the mammalian lymphatic vasculature is venous-derived, the presence of embryonic veins is a prerequisite for lymphatic vasculature formation. The expression of *Coup-TFII* is required to promote and maintain venous identity (You et al. 2005), and very few (if any) LECs are present in *Tie2-Cre;Coup-TFII^{fl/fl}* conditional mutant mouse embryos in which venous fate is lost (Srinivasan et al. 2007). In addition, results from studies of ECs maintained in culture suggest that Coup-TFII activity also helps maintain the LEC phenotype, a role that could be mediated by its protein–protein interaction with *Prox1* (Lee et al. 2009; Yamazaki et al. 2009).

In this study, and by using a variety of animal models, we identify Coup-TFII as a direct *in vivo* activator of *Prox1* expression in venous LEC progenitors. We determined that this activation is mediated by the direct binding of Coup-TFII to a conserved site in the regulatory region of *Prox1* that is required for the initial LEC specification step. Subsequently, interaction of *Prox1* with nuclear hormone receptors (most likely Coup-TFII) is necessary for maintaining *Prox1* expression.

Results

Generation and characterization of the *Prox1^{+/GFP^{Cre}}* line

To better dissect the early steps in the specification of the LEC phenotype and increase our understanding of *Prox1* regulation and function in this process, we took advantage of a novel *Prox1^{+/GFP^{Cre}}* mouse strain that we generated by inserting a *GFP^{Cre}* expression cassette into the *Prox1* genomic locus (Supplemental Fig. 1). In this strain, Cre recombinase was constitutively expressed by all LECs at all time points, and GFP can be used as a reporter of *Prox1* promoter activity. Similar to the previously reported *Prox1^{+/LacZ}* mice (Wigle and Oliver 1999), the generated *Prox1^{+/GFP^{Cre}}* animals were also haploinsufficient, with a reduced rate of postnatal survival in the NMRI background and almost 100% lethality in all other tested backgrounds.

To better characterize this novel mouse strain, we first performed lineage-tracing analysis by crossing the *Prox1^{+/GFP^{Cre}}* strain with the *R26R* reporter line (Soriano 1999). As shown in Supplemental Figure 2, A and B, we observed similar X-gal staining patterns in E11.5 *Prox1^{+/GFP^{Cre}}*;R26R embryos and *Prox1^{+/LacZ}* embryos, a result indicating that *Prox1^{+/GFP^{Cre}}* faithfully recapitulates *Prox1* expression. At this stage, *Prox1⁺*β-gal⁺ LECs were detected around the anterior cardinal vein in a polarized manner (Supplemental Fig. 2C, arrows). Later, at approximately E15.5, all of the GFP⁺ LECs lining the lymph sacs were also β-gal⁺ (Supplemental Fig. 2D, arrows). At postnatal day 1 (P1), we observed *Prox1⁺*β-gal⁺Lyve1⁺ LECs in

the paratracheal lymph plexus (PTLP) (Supplemental Fig. 2E–H) and in the mesentery (Supplemental Fig. 2I–L). In the mesentery, we detected some *Prox1⁺*β-gal⁺Lyve1[−] LECs that most likely correspond to those in the collecting lymphatic vessels (Supplemental Fig. 2L, arrows).

X-gal staining of embryos resulting from crossing *Prox1^{+/GFP^{Cre}}*;R26R mice with wild-type mice showed that all embryos inheriting the *R26R* allele expressed β-gal in all somatic cells. This result indicated that Cre activity is present in the germ cells of *Prox1^{+/GFP^{Cre}}* mice (data not shown). Therefore, when using *Prox1^{+/GFP^{Cre}}* mice, we must be mindful that one of the floxed alleles will be deleted in the germline (Δ), and the other will be deleted in a tissue-specific manner.

Prox1 expression in LECs has two distinct phases

Our previous detailed characterization of *Prox1*-null embryos showed that, contrary to the *Prox1* heterozygous embryos, in these mutant embryos, β-gal-expressing (*Prox1* locus-tagged) ECs are detected for only a few days (E9.75–E11.5) (Wigle and Oliver 1999; Wigle et al. 2002). To identify the cause of this loss of *Prox1* expression and the ultimate fate of those ECs, we generated *Prox1^{+/GFP^{Cre}}* and *Prox1^{LacZ}/GFP^{Cre}* (*Prox1*-null) embryos and compared the numbers of GFP⁺PECAM⁺ cells present in serial sections made along the anterior cardinal vein at E10.5 and E11.5. We found no obvious differences between those embryos at E10.5 (Supplemental Fig. 3A). However, at E11.5, the number of GFP⁺PECAM⁺ cells had nearly doubled in the *Prox1^{+/GFP^{Cre}}* embryos and was moderately reduced in the *Prox1^{LacZ}/GFP^{Cre}* embryos (Supplemental Fig. 3A). We reasoned that this reduction in cell number could have been caused by reduced cell proliferation, increased cell death, or an arrest in *Prox1* and, therefore, GFP expression. Only a small percentage of GFP⁺ ECs were also positive for PH3 (Supplemental Fig. 3B), a marker of proliferating cells, in E10.5 and E11.5 *Prox1^{+/GFP^{Cre}}* and *Prox1^{LacZ}/GFP^{Cre}* embryos. This result supports our previous proposal (Wigle et al. 2002; Srinivasan et al. 2007) that the veins continually generate LECs, and that reduced cell proliferation is not responsible for the observed reduction in cell number in *Prox1^{LacZ}/GFP^{Cre}* embryos. Similarly, we found no obvious differences in the numbers of TUNEL⁺GFP⁺ cells in *Prox1^{+/GFP^{Cre}}* and *Prox1^{LacZ}/GFP^{Cre}* embryos at either time point (Supplemental Fig. 3C–F).

To determine whether *Prox1* expression is arrested in *Prox1*-null cells, we prepared similar sections of E10.5 and E11.5 *Prox1^{+/GFP^{Cre}}* and *Prox1^{LacZ}/GFP^{Cre}* embryos and immunostained them with antibodies against GFP and PECAM, and then analyzed the sections by using confocal imaging. The initial migration of LECs from the veins is independent of *Prox1*, as GFP⁺ cells could be seen migrating from the veins of *Prox1^{LacZ}/GFP^{Cre}* embryos (Fig. 1B,D). At E10.5, the intensity of GFP staining in the ECs of *Prox1^{LacZ}/GFP^{Cre}* embryos was slightly less than that of *Prox1^{+/GFP^{Cre}}* ECs (Fig. 1A,B, arrows; Supplemental Fig. 4); however, at E11.5, the intensity was dramatically reduced in ECs of *Prox1^{LacZ}/GFP^{Cre}* embryos (Fig. 1C,D, arrows;

Supplemental Fig. 4). This observation was further confirmed by image analysis software that also revealed that the intensity of PECAM staining (an internal control) was comparable at E10.5, and was only slightly reduced in *Prox1^{LacZ/GFP}* embryos at E11.5 (Fig. 1E).

Finally, to follow the fate of the *Prox1*-null ECs, we crossed *Prox1^{+/GFP}* and *Prox1^{+/f};R26R* (Harvey et al. 2005) mice to generate *Prox1^{f/GFP};R26R* embryos and analyzed them at E11.5. As mentioned before, at this stage, GFP⁺β-gal⁺PECAM⁺ cells can be detected in and around the anterior cardinal vein of *Prox1^{+/GFP};R26R* embryos (Fig. 1F, arrows). In *Prox1^{f/GFP};R26R* littermates, the level of GFP expression was reduced in many ECs (Fig. 1G, arrows), and GFP⁺β-gal⁺PECAM⁺ cells could be seen on and around the anterior cardinal vein (Fig. 1G, arrowheads). This result confirms that GFP expression is turned off in *Prox1*-null ECs. In addition, it indicates the existence of two phases of LEC development—an early phase during which *Prox1* expression is initiated in venous LEC progenitors, and a

later phase during which *Prox1* expression becomes dependent on the presence of *Prox1*.

Coup-TFII is a direct activator of Prox1 in the embryonic veins

As discussed above, *Sox18* is an upstream regulator of *Prox1* expression in venous LEC progenitors (Francois et al. 2008); however, this gene's activity alone is not sufficient to induce *Prox1* expression in arterial ECs. Therefore, some other factor might cooperate with *Sox18* during the initial induction of *Prox1* expression in venous ECs, and *Coup-TFII* is a potential candidate.

We showed previously that LEC specification is defective in E10.5 *Tie2-Cre;Coup-TFII^{f/f}* mutant mouse embryos in which venous identity is suppressed (You et al. 2005; Srinivasan et al. 2007). Accordingly, we analyzed these mutant embryos in further detail to identify the mechanisms that control the initiation of *Prox1* expression in venous LEC progenitors. One possible argument that explains this phenotype is that the deletion of *Coup-TFII* affected the expression of *Sox18* and, therefore, that of *Prox1*. However, this was not the case. The expression of *Sox18* mRNA appeared to be unaffected in the embryonic veins of E10.5 *Tie2-Cre;Coup-TFII^{f/f}* mutant embryos (Supplemental Fig. 5).

Coup-TFII expression in veins is required to promote venous identity by inhibiting Notch signaling, and the loss of *Coup-TFII* function in *Tie2-Cre;Coup-TFII^{f/f}* embryos results in the ectopic expression of *Notch1* in veins and the consequent dedifferentiation of these cells to an arterial fate (You et al. 2005). Thus, another possible explanation for the defective LEC specification phenotype observed in *Tie2-Cre;Coup-TFII^{f/f}* mutant embryos is that ectopic Notch signaling suppresses *Prox1* expression. To test this possibility, we attempted to rescue the

Figure 1. Maintenance of *Prox1* expression in LECs requires *Prox1*. (A,B) Compared with that in E10.5 *Prox1^{+/GFP}* embryos (A), *Prox1* expression in *Prox1^{LacZ/GFP}* embryos (B, arrows) is moderately reduced in the ECs migrating from the anterior cardinal vein (CV), as indicated by immunostaining for GFP (red). (C,D) At E11.5, the level of GFP expression remains high in the LECs of *Prox1^{+/GFP}* embryos (C), whereas it is down-regulated in the *Prox1*-null ECs of *Prox1^{LacZ/GFP}* littermates (D, arrows). (E) Image analysis was performed on GFP⁺ cells from eight identical level sections for each embryo. At E10.5, quantification of GFP and PECAM intensities indicates a moderate reduction in GFP expression in the ECs of *Prox1^{LacZ/GFP}* embryos; PECAM levels appear comparable. At E11.5, the GFP level is markedly reduced in *Prox1^{LacZ/GFP}* ECs. PECAM expression is only moderately reduced in *Prox1*-null ECs. (F) At E11.5, GFP⁺PECAM⁺β-gal⁺ cells line the cardinal vein and migrate from it in *Prox1^{+/GFP};R26R* embryos (arrows). A few mesenchymal cells weakly express GFP. Correspondingly, these cells are also β-gal⁺ (arrowhead). (G) GFP expression is weak in numerous β-gal⁺PECAM⁺ cells of E11.5 *Prox1^{f/GFP};R26R* embryos (arrows). Numerous GFP⁺PECAM⁺β-gal⁺ cells are also located on and outside the cardinal vein (arrowhead). The neural tube is oriented toward the top of A–D and toward the right side in F and G. (CV) Anterior cardinal vein; (LS) lymph sacs; (A) dorsal aorta. Bar, 50 μm.

loss of *Prox1*⁺ LECs by deleting *Rbpj*, the primary mediator of Notch signaling (Kato et al. 1997; Tanigaki et al. 2002), from venous ECs. To this end, E10.0 *Tie2-Cre;Coup-TFII*^{fl/fl}, *Tie2-Cre;Rbpj*^{fl/fl}, and *Tie2-Cre;Coup-TFII*^{fl/fl};*Rbpj*^{fl/fl} embryos were generated and analyzed. We bred *Tie2-Cre;Coup-TFII*^{fl/fl};*Rbpj*^{fl/fl} mice with each other, and from 17 litters we obtained 173 E10.0 embryos. Of those, 21 were *Tie2-Cre;Coup-TFII*^{fl/fl}, which is in the expected Mendelian ratio (one out of eight); however, we collected only three *Tie2-Cre;Rbpj*^{fl/fl} and two *Tie2-Cre;Coup-TFII*^{fl/fl};*Rbpj*^{fl/fl} embryos. This indicates that the absence of Notch signaling affects the survival of the embryos at a much earlier time point. We analyzed two embryos from each of the genotypes. As expected, the expression of the arterial-specific marker connexin 40 (CX40) (Delorme et al. 1997) was restricted to the arteries of control embryos (Supplemental Fig. 6A,B). Consistent with the role of Notch signaling in the maintenance of arterial identity (Krebs et al. 2004), CX40 expression was lost in the arteries of *Tie2-Cre;Rbpj*^{fl/fl} embryos (Supplemental Fig. 6D,E). In *Tie2-Cre;Coup-TFII*^{fl/fl} embryos, in addition to the normal CX40 expression in arteries (Supplemental Fig. 6G,H, arrowheads), ectopic expression was detected in certain restricted regions of the mutant veins (Supplemental Fig. 6G,H, arrows) that seem to also contain abnormal arterio-venous shunts (AVM) (Supplemental Fig. 6H, red arrow). As expected, in *Tie2-Cre;Rbpj*^{fl/fl};*Coup-TFII*^{fl/fl} embryos, CX40 expression remained dramatically reduced in arteries (Supplemental Fig. 6J,K). Importantly, we did not observe ectopic expression of CX40 in the mutant veins (Supplemental Fig. 6J,K), indicating that the loss of *Rbpj* at least partially rescued the venous identity in *Tie2-Cre;Coup-TFII*^{fl/fl} embryos.

Next, immunohistochemistry against *Prox1* and *Lyve1* revealed that their expression was normal in control and *Tie2-Cre;Rbpj*^{fl/fl} embryos (Supplemental Fig. 6C,F), a result indicating that Notch signaling is not required for LEC specification. As reported previously (Srinivasan et al. 2007), the number of *Prox1*-expressing LECs was dramatically reduced in *Tie2-Cre;Coup-TFII*^{fl/fl} embryos (Supplemental Fig. 6I). In *Tie2-Cre;Coup-TFII*^{fl/fl};*Rbpj*^{fl/fl} embryos, the number of *Prox1*-expressing LECs remained dramatically reduced (Supplemental Fig. 6L).

Together, these results indicate that the loss of venous identity, but not that of LECs, can be rescued in *Tie2-Cre;Coup-TFII*^{fl/fl} embryos upon removal of ectopic Notch signaling from the mutant venous ECs. They also suggest that, in addition to suppressing Notch signaling, Coup-TFII activity is required during LEC specification. Furthermore, only one-fifth of the number of LECs detected in control embryos were counted in E10.5 *Tie2-Cre;Coup-TFII*^{fl/fl} embryos (Srinivasan et al. 2007), and these LECs were also Coup-TFII⁺ (Supplemental Fig. 7). This result indicates a cell-autonomous requirement for Coup-TFII in LEC specification, and suggests that, in that process, Coup-TFII activity lies upstream of *Prox1*.

To investigate whether Coup-TFII directly regulates *Prox1* expression, we first used the TRANSFAC Bioinformatics program (Matys et al. 2006) to search for putative

Coup-TFII DNA-binding motifs (CBS) (Fig. 2A) in putative regulatory regions of available *Prox1* genomic sequences from humans, chimpanzees, mice, and rats. The regions were located 5 kb upstream of the noncoding exon 1 and in intron 1. We identified two putative Coup-TFII-binding sites in mice and rats, five in chimpanzees, and six in humans (Fig. 2B). Interestingly, the binding site located ~9.5 kb upstream of the ORF of mouse *Prox1* is conserved among the four mammals (Fig. 2B, red circles). Furthermore, by performing multiple sequence alignment, we found that this sequence is also conserved among other mammals whose genomic sequences are available (Fig. 2C).

To determine whether the conserved recognition motif identified in the mouse behaves as a Coup-TFII-binding site, we amplified a 201-base-pair (bp) DNA fragment containing this motif and performed electrophoretic mobility shift assays (EMSA) using 293T cells transfected with a *COUP-TFII* expression plasmid. The radiolabeled probe containing the conserved Coup-TFII-binding site shifted only slightly in control cell lysates (Fig. 2D, lane 2), a result that may have been caused by endogenous COUP-TFII (see below); in contrast, the cell lysates in which COUP-TFII was expressed ectopically showed a strong band shift (Fig. 2D, lane 3). Migration of the labeled probe was further retarded upon addition of a monoclonal antibody against COUP-TFII (Fig. 2D, lane 4), indicating that the shift and the supershift were specific to COUP-TFII binding to the probe. The binding specificity was further confirmed by the reduced amount of complex that formed when 250-fold excess of non-radioactive probe was added (Fig. 2D, lane 5), and by the fact that this competition was less efficient when two of the highly conserved TG residues present in the Coup-TFII-binding site were mutated to AA residues in the nonradioactive probe (Fig. 2D, lane 6). No specific binding was detected when we repeated the EMSA assay using a probe for a nonconserved putative Coup-TFII-binding site (data not shown).

Next, we performed chromatin immunoprecipitation (ChIP) analysis on isolated human LECs by using a rabbit polyclonal antibody specific for COUP-TFII and TaqMan-based real-time PCR. Using this approach, we detected a significant ($P \leq 0.01$) enrichment when amplifying the identified conserved COUP-TFII-binding site in comparison with a nonconserved COUP-TFII-binding site or a region located 40 kb downstream from the ATG (Fig. 2E).

We further confirmed this transcriptional regulation by performing a luciferase assay. Briefly, six conserved Coup-TFII-binding sites were inserted in tandem into the pGL3 basic luciferase reporter plasmid (6XCBS). Two additional versions of this reporter were generated by mutating 4 or 8 conserved nucleotides in each of the 16-nucleotide (nt) CBS repeats (6XmCBS1 and 6XmCBS2, respectively). 293T cells were then transfected with either of these reporter plasmids, with or without a COUP-TFII-expressing plasmid. Small amounts of COUP-TFII are expressed endogenously by 293T and NIH 3T3 cell lines (Fig. 2F). Cells into which only the 6XCBS reporter plasmid was transfected showed higher luciferase reporter activity

than those containing the pGL3 basic control plasmid (Fig. 2G). This activity increased when the cells were cotransfected with increasing concentrations of COUP-TFII expression plasmid (Fig. 2G). In contrast, cells that were transfected with the 6XmCBS1 reporter plasmid with or without the COUP-TFII expression plasmid showed significantly less activity than cells transfected with the 6XCBS plasmid (Fig. 2G). The activity of the 6XmCBS2 plasmid was at a basal level and comparable with that of the control plasmid (Fig. 2G). Together, these results argue that Coup-TFII binds to the identified conserved site located in the *Prox1* regulatory region, and is a direct *in vivo* regulator of *Prox1* expression in

venous LEC progenitors during the early phases of LEC specification.

Coup-TFII is required to maintain Prox1 expression during the early phase of LEC specification

Prox1 expression in the developing lymphatic vasculature occurs in two separate phases: an initiation phase, and a *Prox1*-dependent maintenance phase. We established here that Coup-TFII plays an early role in the initiation of *Prox1* expression in venous LEC progenitors. Results from ECs maintained in culture suggest that Coup-TFII activity also maintains the LEC phenotype by

Figure 2. Coup-TFII binds directly to a conserved site present in the *Prox1* upstream regulatory region. (A) Coup-TFII recognizes a 16-nt motif (CBS) that consists of two similar 8-nt repeats. (B) A DNA region located 5 kb upstream of the noncoding exon 1 and the entire intron 1 (upstream of the ATG translational start codon) of human (Hs), mouse (Mm), rat (Rn), and chimpanzee (Pt) *Prox1* was analyzed, and putative CBSs were identified (blue bars). Upward bars indicate those in the sense orientation, and downward bars indicate those in the antisense orientation. Red circles highlight the CBS that is conserved among all species tested. (C) The identified CBS is also conserved among other mammals whose DNA sequences are available. The consensus DNA sequence is underlined. The colors above the nucleotides indicate the consensus strength, with red being the strongest and blue being the weakest. (D) The conserved CBS from the mouse *Prox1* gene was amplified by PCR, and the radiolabeled probe was generated using 32 P-dCTP. EMSA was performed using 293T cell lysates with or without ectopically expressed COUP-TFII. (Lane 1) Probe alone (asterisk). (Lane 2) Labeled probe incubated with GFP-transfected 293T cell lysate. (Lane 3) Labeled probe incubated with COUP-TFII-transfected 293T cell lysate. The shift in the mobility of the probe is seen (arrow). (Lane 4) Probe incubated with COUP-TFII-transfected 293T cell lysate and a mouse monoclonal antibody against COUP-TFII. A supershifted band (arrowhead) can be seen. (Lane 5) An excess (250-fold) of nonradiolabeled probe efficiently competed with the binding of COUP-TFII to the radiolabeled probe. (Lane 6) Replacement of the two highly conserved TG residues in the nonradiolabeled probe reduced this competition. (E) ChIP was performed on human LECs maintained in culture by using a rabbit polyclonal antibody against COUP-TFII. Real-time PCR was carried out using the pulled-down DNA fragment as a template and primers and probes specific for the conserved CBS, a nonconserved CBS (control 1), or a nonspecific site 40 kb downstream from the ATG (control 2). When compared with controls, a statistically significant ($P \leq 0.01$) enrichment was observed for the conserved CBS. (F) Western blotting shows the expression of COUP-TFII in 293T and NIH 3T3 cells commonly used for luciferase assays. (G) Dual luciferase assay was carried out using the generated reporters containing six consecutive conserved CBSs that are wild-type (6XCBS), carrying a mutation in 4 of the 16 nt (6XmCBS1), or carrying a mutation in 8 of the 16 nt (6XmCBS2). The 6XCBS showed endogenous activity caused by the presence of COUP-TFII in the cells. This activity increased with increasing concentrations of the COUP-TFII expression plasmid. Although the 6XmCBS1 showed reduced endogenous activity, it moderately responded to ectopic COUP-TFII. The 6XmCBS2 did not show any endogenous activity and did not respond to COUP-TFII.

interacting with *Prox1* (Lee et al. 2009; Yamazaki et al. 2009). To assess whether Coup-TFII is required to maintain the LEC phenotype in vivo, we first performed a detailed analysis of Coup-TFII expression in developing lymphatics by using a Coup-TFII-specific antibody with antibodies against *Prox1* or *Lyve1* (Supplemental Fig. 8A,C, E). We also took advantage of the fact that conditional deletion of *Coup-TFII* activates a *lacZ* reporter only in those tissues where the gene was deleted (Takamoto et al. 2005; You et al. 2005). Thus, we bred *Prox1^{+/CreERT2}* mice (Srinivasan et al. 2007) with *Coup-TFII^{+/f}* mice (Takamoto et al. 2005) and exposed the double-heterozygous animals to tamoxifen (TM) at different time points to activate the *lacZ* reporter (Supplemental Fig. 8B,D,F). In agreement with a previous study (Lee et al. 2009), Coup-TFII was coexpressed with *Prox1* in E11.5 LECs located in and around the cardinal vein (Supplemental Fig. 8A). By X-gal and *Prox1* costaining (Supplemental Fig. 8B), or by immunostaining with the LEC marker *Lyve1* (Supplemental Fig. 8C), we also detected Coup-TFII expression in the lymph sacs at E12.5 and E14.5, respectively. Whole-mount X-gal staining of E15.5 *Prox1^{+/CreERT2};Coup-TFII^{+/f}* embryos exposed to TM at E10.5 showed that Coup-TFII is expressed in the peripheral lymphatics of these embryos (Supplemental Fig. 8D). At E16.5, coimmunostaining for Coup-TFII, *Prox1*, and *Lyve1* showed that Coup-TFII is expressed in the *Prox1⁺Lyve1⁺* lymphatic vessels near the pericardial cavity (Supplemental Fig. 8E). Finally, whole-mount X-gal staining of the ears of P15 *Prox1^{+/CreERT2};Coup-TFII^{+/f}* pups exposed to TM between P1 and P10 showed that Coup-TFII is expressed in the dermal lymphatics (Supplemental Fig. 8F).

To identify possible functional roles of *Coup-TFII* in developing lymphatics once *Prox1* expression in LEC progenitors has already been initiated, we first generated *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{+/f} mice by crossing *Prox1^{+/GFP^{Cre}}* with *Coup-TFII^{+/f}* mice. From those crosses, which resulted in nearly 400 pups, only 10% were *Prox1^{+/GFP^{Cre}}*,

and 2.5% were *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{+/f}. This reduced number of *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{+/f} mice may have been caused by a cooperative effect between *Prox1* and Coup-TFII in normal development. We then generated *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{Δ/f} embryos by crossing *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{+/f} mice with *Coup-TFII^{+/f}* or *Coup-TFII^{Δ/f}* mice, and analyzed at least three mutant embryos from independent crosses at each stage. Normally, at E11.5, strong *Prox1* expression is detected in the cardinal vein and LECs that start to move away from the cardinal vein (Fig. 3A). However, in *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{Δ/f} littermates, very few (if any) weakly *Prox1*-expressing LECs were observed on or outside the cardinal veins (Fig. 3B, arrow). Similarly, at E13.5, the *Prox1⁺* lymph sacs seen in control embryos (Fig. 3D) were missing in *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{Δ/f} littermates (Fig. 3E). Consistently, at E16.5, no *Prox1⁺* LECs were observed in the dermis, lung, or mesentery of *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{Δ/f} embryos (data not shown). The complete absence of LECs observed in *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{Δ/f} embryos was similar to that seen in *Prox1^{LacZ/GFP^{Cre}}* embryos. Analysis of *Prox1^{LacZ/GFP^{Cre}}* embryos showed that *Prox1* is required to maintain *Prox1* expression (Fig. 1). Because in *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{Δ/f} mice *Coup-TFII* is deleted soon after the initiation of *Prox1* expression (once LEC specification has started), we conclude that, in addition to that of *Prox1*, the activity of Coup-TFII is required for the maintenance of *Prox1* expression in early differentiating LECs.

In this scenario, LECs may have a positive feedback loop in which Coup-TFII activates the expression of *Prox1*, which in turn maintains Coup-TFII expression. To test this possibility, and to identify the mechanisms by which Coup-TFII and *Prox1* cooperate in the maintenance of *Prox1* expression, we analyzed Coup-TFII expression in the GFP⁺ cells of E11.0 *Prox1^{GFP^{Cre}/GFP^{Cre}}* embryos. Normal Coup-TFII expression was detected in the GFP⁺ (*Prox1*-null) ECs (Supplemental Fig. 9A,B), a result indicating that *Prox1* is not necessary to maintain

Figure 3. Interaction between Coup-TFII and *Prox1* is required to maintain *Prox1* expression in LECs. (A) At E11.5, *Prox1*-expressing LECs (red) are seen in and around the anterior cardinal vein (CV) of *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{+/f} embryos. (B) Just a few *Prox1⁺* LECs (arrow) are seen in *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{Δ/f} littermates. (C) E11.5 *Prox1^{NRMut}/GFP^{Cre}* embryos expressing a form of *Prox1* mutated in the nuclear hormone receptor-binding site also have a reduced number of LECs (arrows). (D) At E13.5, the lymph sacs (LS) lined by *Prox1⁺* LECs are seen in control embryos. However, at this stage, no LECs are seen in *Prox1^{+/GFP^{Cre}}*;Coup-TFII^{Δ/f} (E) or *Prox1^{NRMut}/GFP^{Cre}* (F) embryos. PECAM is shown in green. The neural tube is oriented toward the left side of all panels. (JV) Jugular vein; (SG) sympathetic ganglia. Bar, 50 μ m.

Coup-TFII expression. Another possibility is that *Prox1* maintains the expression of *Sox18*, which cooperates with Coup-TFII to maintain that of *Prox1*. However, we observed no obvious changes in the expression of *Sox18* in E11.0 *Prox1^{GFPcre/GFPcre}* embryos (Supplemental Fig. 9C–H). These results indicate that, during the LEC specification phase, Coup-TFII and *Sox18* are necessary but not sufficient to maintain *Prox1* expression, and that *Prox1* is required during this stage to maintain its own expression.

Previous in vitro studies have suggested a physical interaction between Coup-TFII and *Prox1* in LECs (Lee et al. 2009; Yamazaki et al. 2009). Therefore, because *Prox1* and Coup-TFII are required for the maintenance of *Prox1* expression, once Coup-TFII initiates *Prox1* expression in venous LEC progenitors, they may interact with each other. To test this possibility, we generated a knock-in mouse line in which two putative nuclear hormone receptor-binding sites (Liu et al. 2003; Qin et al. 2004; Steffensen et al. 2004; Wang et al. 2008; Lee et al. 2009; Yamazaki et al. 2009) in *Prox1* were mutated (*Prox1^{NRMut}*) (Supplemental Fig. 10). This mutated version of *Prox1* contained a synthetic tag (avitag) (Supplemental Fig. 10). Similar to wild-type *Prox1*, avitag-containing wild-type *Prox1* was also capable of activating the expression of LEC-specific markers when expressed ectopically in blood ECs maintained in culture (Supplemental Fig. 11). This result indicates that the inclusion of the avitag did not affect *Prox1* activity. Unlike *Prox1^{+/-LacZ}*, *Prox1^{+/-NRMut}* embryos did not exhibit any obvious edema at E15.5 (Supplemental Fig. 12A,B), and *Prox1^{+/-NRMut}* pups were born at normal Mendelian ratios (data not shown). These results indicate that the mutation of the nuclear hormone-binding site did not completely abolish *Prox1* activity. Analysis of *Prox1^{NRMut/GFPcre}* embryos, which express only the mutant form of *Prox1*, revealed the presence of a few scattered weakly *Prox1*-expressing LECs at E11.5 (Fig. 3C, arrows) and none at E13.5 (Fig. 3F). Analysis of sections along the anteroposterior axis of E11.5 *Prox1^{+/-GFPcre}*, *Prox1^{+/-GFPcre}*; *Coup-TFII^{Δlf}*, and *Prox1^{NRMut/GFPcre}* embryos identified only a few *Prox1⁺* LECs in the last two mutant strains (Supplemental Fig. 13).

Next, we analyzed the generated *Prox1^{NRMut/NRMut}* embryos. Contrary to their heterozygous littermates, the homozygous embryos exhibited severe edema at E13.5 (Supplemental Fig. 12C,D). Comparison of transverse section at the level the jugular lymph sacs of control (Supplemental Fig. 12E) and *Prox1^{NRMut/NRMut}* (Supplemental Fig. 12F) embryos showed a significant reduction in the number of *Prox1⁺* LECs in the mutant embryos. These mutant LECs did not express the normal levels of other LEC markers, such as *Nrp2* and *Lyve1* (Supplemental Fig. 12F, arrow). Furthermore, serial sectioning along the anteroposterior axis of these mutant embryos revealed the presence of only a few *Prox1⁺* LECs that abnormally aggregated around the jugular vein (Supplemental Fig. 12G–J).

The phenotype observed in *Prox1^{NRMut/GFPcre}* embryos and *Prox1^{NRMut/NRMut}* embryos does not allow us to conclude whether this phenotype is caused by the loss of interaction between *Prox1* and Coup-TFII or because in-

teraction of *Prox1* with other nuclear hormone receptors is required to regulate *Prox1* expression. However, the phenotypic similarity of *Prox1^{NRMut/NRMut}* and *Prox1^{NRMut/GFPcre}* embryos with that of *Prox1^{+/-GFPcre}*; *Coup-TFII^{Δlf}* embryos strongly suggested that the Coup-TFII–*Prox1* interaction is necessary to maintain *Prox1* expression and, therefore, LEC identity during the LEC specification stage.

Prox1 expression in specified LECs is independent of Coup-TFII expression

Similar to *Prox1* expression, that of Coup-TFII in LECs is maintained throughout embryonic and postnatal stages; therefore, we tested whether Coup-TFII activity was constantly required to maintain *Prox1* expression in LECs during developmental lymphangiogenesis. To do this, we took advantage of the previously generated TM-inducible *Prox1^{+/-CreERT2}* mouse strain (Srinivasan et al. 2007). We exposed *Prox1^{+/-CreERT2}*; *Coup-TFII^{+/+}* and *Prox1^{+/-CreERT2}*; *Coup-TFII^{Δlf}* embryos to TM (5 mg/40 g body weight of the pregnant dams) at various developmental time points (E10.5–E14.5) and analyzed them at E15.5. The most representative from at least three independent crosses is presented. *Prox1^{+/-CreERT2}*; *Coup-TFII^{Δlf}* embryos exposed to TM at E10.5–E12.5 exhibited edema and blood-filled dermal vessels (Fig. 4B–D).

Conditional deletion of *Coup-TFII* activated the *lacZ* reporter wherever the gene was deleted. Accordingly, whole-mount staining performed in the *Prox1^{+/-CreERT2}*; *Coup-TFII^{Δlf}* conditional mutant embryos showed a reduced number of X-gal-stained superficial vessels; the earlier the embryos were exposed to TM, the more severe the reduction (Fig. 4F–H). Analysis of *Prox1^{+/-CreERT2}*; *Coup-TFII^{Δlf}* embryos exposed to TM at E10.5 or E11.5 showed that the expression of LEC markers in regions with few β -gal⁺ vessels was either completely absent or severely reduced, thereby confirming that the lack of X-gal staining indicates a lack of lymphatic vessels (Supplemental Fig. 14). Further analysis showed that the lymph sacs of these conditional mutant embryos were also drastically mispatterned and reduced in size (Supplemental Fig. 14B, arrow). Sectioning of *Prox1^{+/-CreERT2}*; *Coup-TFII^{Δlf}* embryos exposed to TM at E12.5 revealed a substantial reduction in the expression of the LEC markers *Nrp2*, *Lyve1*, and podoplanin in these blood-filled lymphatic vessels, although *Prox1* levels appeared normal (Fig. 5). We also immunostained for *Prox1* and Coup-TFII or β -gal to determine whether the remaining *Prox1⁺* LECs are the result of incomplete deletion of *Coup-TFII*. Expression of this gene was markedly reduced or completely absent in the surviving *Prox1⁺* cells (Fig. 6), thereby excluding this possibility.

In contrast to the phenotypic alterations observed upon early TM administration (E10.5–E12.5), few (<10%) *Prox1^{+/-CreERT2}*; *Coup-TFII^{Δlf}* embryos displayed lymphatic reduction or lymphatic defects when exposed to TM at E13.5, and no obvious lymphatic vascular defects were observed when TM was administered at later developmental or postnatal time points (see below; data not shown). For example, *Prox1^{+/-CreERT2}*; *Coup-TFII^{Δlf}* embryos and their control littermates were exposed to TM at E14.5 and E15.5, and the phenotypically normal embryos were

Figure 4. Coup-TFII has a time-dependent role in the regulation of lymphatic vascular development. (A–D) *Prox1^{+/CreERT2};
Coup-TFII^{fl/fl}* (A) and *Prox1^{+/CreERT2};
Coup-TFII^{fl/fl}* (B–D) embryos were exposed to TM at the indicated time points and isolated at E15.5. Blood-filled superficial vessels and edema (arrows) are observed in *Prox1^{+/CreERT2};
Coup-TFII^{fl/fl}* embryos. (E–H) The above embryos were whole-mount X-gal-stained for β -gal activity. (E) The X-gal⁺ LECs are seen forming the dermal lymphatic plexus in control embryos. (F) In contrast, in *Prox1^{+/CreERT2};
Coup-TFII^{fl/fl}* embryos exposed to TM at E10.5, the superficial lymphatic plexus is nearly absent. (G,H) The number of superficial X-gal⁺ cells increases concomitantly with the later time of TM exposure. However, the overall size of the lymphatic plexus remains smaller than that of control embryos.

analyzed at E16.5 by either X-gal staining or immunostaining of sections with antibodies against *Prox1* and Coup-TFII. The X-gal staining confirmed efficient deletion of *Coup-TFII* in the superficial lymphatics, and the immunostaining showed a substantial reduction in the expression of Coup-TFII in LECs (Supplemental Fig. 15). These results indicate that Coup-TFII function is not required after E13.5, and that the maintenance of *Prox1* expression becomes independent of Coup-TFII at this stage.

Discussion

Previous work identified *Sox18* as an upstream regulator of *Prox1* expression in the anterior cardinal vein (Francois et al. 2008). However, *Prox1* expression is not induced in embryonic arteries that also express *Sox18*. One possible explanation is that some arterial-specific gene (e.g., Notch pathway or *Sox18*) represses *Prox1* induction. Another possible explanation is that, in veins, some other factors cooperate with *Sox18* in the induction of *Prox1*. On the basis of our results, we propose that Coup-TFII is at least one of these factors.

We determined that, during LEC differentiation, three phases of *Prox1* regulation are associated with the progress of the stepwise process leading to LEC differentiation (Fig. 7). Here we demonstrated that Coup-TFII activity is necessary for the direct activation of *Prox1* expression in venous LEC progenitors. However, the few days of delay between the appearance of Coup-TFII-expressing veins and the detection of the first *Prox1*-expressing LECs argues that venous fate and, therefore, Coup-TFII expression, although necessary, are not sufficient to initiate LEC differentiation, and that other factors might be required. Therefore, we speculate that the initial phase of *Prox1* induction requires the cooperative activity of *Coup-TFII* and *Sox18*.

The second phase of *Prox1* regulation occurs once *Prox1* expression is induced and LEC specification is progressing (Fig. 7). During this phase, the Coup-TFII–

Prox1 interaction is required to maintain *Prox1* expression in early differentiating LECs. The third phase is a maintenance phase that depends on *Prox1* but not Coup-TFII. ChIP analysis failed to identify specific binding of *Prox1* to the identified conserved Coup-TFII-binding site (data not shown). After transient interaction with Coup-TFII, *Prox1* may be recruited to a different site located in its own promoter and regulate its own expression. Alternatively, the Coup-TFII–*Prox1* complex may activate another transcription factor that, in turn, regulates *Prox1* expression. Both of these possibilities are highlighted in our model (Fig. 7).

Although Coup-TFII is expressed in LECs at all time points, and most likely continues to interact with *Prox1* (Lee et al. 2009; Yamazaki et al. 2009), the functional significance of this interaction appears to become subtle after E13.5. It will be interesting to determine whether this interaction has any significant role in conditions such as cancer- or inflammation-induced lymphangiogenesis or wound healing.

Finally, in humans, *COUP-TFII* maps to chromosome 15q25, a region associated with the autosomal-recessive lymphedema-cholestasis syndrome (also known as Aagaenae syndrome) (Bull et al. 2000). Coup-TFII also regulates metabolism (Li et al. 2009); therefore, this gene may be affected in patients with Aagaenae syndrome. Linkage analysis has shown that the mutation in these patients is present in a 6 cM genomic region in 15q25 (Bull et al. 2000) that is ~ 3 Mb from the coding region of *COUP-TFII*. However, Aagaenae syndrome is autosomal-recessive and genetically heterogeneous (Fruhworth et al. 2003); mutations in the coding region of *COUP-TFII* most likely result in embryonic lethality; therefore, a reduction in the levels of COUP-TFII expression may cause Aagaenae syndrome. Consistent with this hypothesis, we occasionally observed edema in *Coup-TFII^{fl/fl}* mouse embryos (Supplemental Fig. 16), indicating that hypomorphic mutations in *COUP-TFII* might result in lymphatic defects.

Figure 5. Conditional deletion of *CoupTFII* using *Prox1*^{+/CreERT2}; *CoupTFII*^{+/f} embryos reduces the expression of LEC markers. *Prox1*^{+/CreERT2}; *CoupTFII*^{+/f} and *Prox1*^{+/CreERT2}; *CoupTFII*^{+/f} embryos were exposed to 5 mg TM at E12.5 and were analyzed at E15.5 by immunostaining of sections with different LEC markers. (A) *Prox1* (red) and *Nrp2* (green) are coexpressed in the LECs of a peripheral lymphatic vessel of *Prox1*^{+/CreERT2}; *CoupTFII*^{+/f} embryos. (B) However, in *Prox1*^{+/CreERT2}; *CoupTFII*^{+/f} embryos, these vessels are dilated and mispatterned, and the expression of *Nrp2* is substantially reduced. (C) *Prox1* (green) and *Lyve1* (red) are coexpressed in the peripheral lymphatic vessel (arrow) of *Prox1*^{+/CreERT2}; *CoupTFII*^{+/f} embryos. (D) In contrast, the lymphatic vessels of *Prox1*^{+/CreERT2}; *CoupTFII*^{+/f} embryos are dilated, and *Lyve1* expression is down-regulated in the *Prox1*⁺ LECs of the peripheral lymphatic vessels (arrows). The scattered *Prox1*⁺ *Lyve1*⁺ cells are macrophages. (E,F) Deletion of the floxed *Coup-TFII* allele results in the activation of the *LacZ* reporter gene that expresses β -gal (red). (E) Costaining with the LEC marker podoplanin (green) shows that these markers are coexpressed in the lymphatic vessels of *Prox1*^{+/CreERT2}; *CoupTFII*^{+/f} embryos. (F) In contrast, the expression of podoplanin is substantially reduced in the lymphatic vessels of *Prox1*^{+/CreERT2}; *CoupTFII*^{+/f} embryos. The neural tube is oriented toward the bottom of A, and toward the right side of B–F. Bar, 50 μ m.

Materials and methods

Mice

The generation of *Tie2-Cre*, *Rbpj*^{+/f}, *Prox1*^{+/f}, *Coup-TFII*^{+/f}, and *Prox1*^{+/CreERT2} mutant mice has been described previously (Kisanuki et al. 2001; Tanigaki et al. 2002; Harvey et al. 2005; Takamoto et al. 2005; Srinivasan et al. 2007). To generate the

Prox1^{+/GFP^{Cre} strain (Supplemental Fig. 1), we inserted a *GFP^{Cre}* fusion protein cassette downstream from the *Prox1* translational start site. For positive selection, we inserted a neomycin-resistant gene cassette downstream from *GFP^{Cre}* in the opposite orientation. For negative selection, we inserted a thymidine kinase gene outside the recombination arms.}

To generate the *Prox1*^{+/N^Rmut} mouse strain, we used PCR to generate a 2.5-kb fragment upstream of the ATG of mouse *Prox1* and a 1.5-kb fragment containing a fusion of synthetic avitag-encoding sequence and *Prox1* exon 1 carrying the mutation in the sequence coding for the nuclear hormone-binding site, and then cloned the fragments into the PL452 plasmid. Avitag is a 17-amino-acid peptide (MSGNDIFEAQKIEWHE) that can be biotinylated by the BirA biotin ligase, and therefore can be used for immunoprecipitation of tagged proteins using streptavidin (Schatz 1993; Scholle et al. 2004). This plasmid contained a neomycin selection cassette flanked by *LoxP* sites for positive selection and a cDNA cassette coding for diphtheria toxin chain A for negative selection.

Both targeting constructs were electroporated into W9.5 embryonic stem cells. Following selection and screening by Southern blot, the correctly targeted embryonic stem cells were used for the generation of chimeric mice. The neomycin cassette in the F1 *Prox1*^{+/N^Rmut} mouse strain was removed by crossing it with a *Vav-iCre* transgenic line that is expressed in the germline (de Boer et al. 2003). All described mouse experiments were approved by the St. Jude Children's Research Hospital Animal Care and Use Committee.

Antibodies

The primary antibodies used were rabbit anti-*Prox1* (AngioBio), goat anti-*Prox1* (R&D Systems), rabbit anti- β -gal (MP Biomedicals), chicken anti- β -gal (Abcam), rat anti-PECAM (BD Pharmingen), rabbit anti-GFP (Molecular Probes), rabbit anti-CX40 (Alpha Diagnostic International), guinea pig anti-*Lyve1* (our own), goat anti-*Nrp2* (R&D Systems), goat anti-Reelin (R&D Systems), hamster anti-podoplanin (Hybridoma Bank), mouse anti-COUP-TFII (Perseus Proteomics), rabbit anti-COUP-TFII (Tripodi et al. 2004), and mouse anti-PH3 (Upstate Biotechnologies). Secondary antibodies were Cy3-conjugated donkey anti-rabbit (Jackson ImmunoResearch Laboratories), Cy3-conjugated donkey anti-mouse (Jackson ImmunoResearch Laboratories), Cy3-conjugated goat anti-chicken (Rockland), Cy3-conjugated donkey anti-goat (Jackson ImmunoResearch Laboratories), Cy3-conjugated goat anti-hamster (Jackson ImmunoResearch Laboratories), Alexa 488-conjugated donkey anti-rat (Molecular Probes), Alexa 488-conjugated donkey anti-goat (Molecular Probes), Alexa 488-conjugated goat anti-chicken (Molecular Probes), Alexa 488-conjugated goat anti-guinea pig (Molecular Probes), Alexa 488-conjugated donkey anti-goat (Molecular Probes), Alexa 488-conjugated goat anti-hamster (Molecular Probes), Alexa 488-conjugated donkey anti-mouse (Molecular Probes), Cy5-conjugated donkey anti-guinea pig (Jackson ImmunoResearch Laboratories), and Cy5-conjugated donkey anti-rat (Jackson ImmunoResearch Laboratories). Mouse anti-COUP-TFII was used for immunostaining of E10.5 sections, and rabbit anti-COUP-TFII was used for staining sections at later embryonic stages. The sections were mounted using VectaShield mounting media containing DAPI (Vector Laboratories).

Image analysis

Tissue sections prepared on a cryostat were immunostained with antibodies specific for GFP and PECAM and then photographed with a confocal laser-scanning microscope (Zeiss) at identical LASER power and settings. Subsequently, the images were

Figure 6. *Prox1* expression is normal in the remaining *Coup-TFII*-null LECs of E15.5 *Prox1*^{+/CreERT2};*Coup-TFII*^{fl/fl} embryos exposed to TM at E12.5. (A) At E15.5, dermal lymphatic vessels are lined by *Prox1*⁺*Coup-TFII*⁺ LECs in wild-type embryos. (B) The *Prox1*⁺ LECs of *Prox1*^{+/CreERT2};*Coup-TFII*^{fl/fl} littermates are negative for *Coup-TFII*. (C) β -gal staining shows the efficient deletion of *Coup-TFII* in the remaining *Prox1*-expressing LECs. The neural tube is oriented toward the right side of all panels. Bar, 50 μ m.

analyzed using NIS Elements AR 3.0 image analysis software (Nikon) to quantify the intensities of the fluorochromes.

Bioinformatics

We downloaded 5-kb upstream sequences, the 5' untranslated region (UTR), and the first intron (up to start site ATG) of *Prox1* genes from human, mouse, rat, and chimpanzee data on the University of California at Santa Cruz genome browser. We searched the V\$ARP1_1 matrix (for putative *Coup-TFII*-binding sites) derived from Transfac version 2009.1 (Matys et al. 2006) and mapped to the upstream sequences using matrix scan (Thomas-Chollier et al. 2008). Multiple sequence alignment was performed using Lasergene MegAlign software (DNASTAR, Inc.).

EMSA

EMSA was carried out as described previously (Jeong et al. 2008), with the exception of 293T cells being used instead of COS7 cells for the ectopic expression of COUP-TFII. For ectopic expression,

the CMV6-XL5 expression plasmid containing the full-length COUP-TFII cDNA was purchased from Origene.

The probe was generated by amplifying the *Coup-TFII*-binding site identified in the mouse *Prox1* regulatory region using the specific forward and reverse primers EMSA1 and EMSA2 (Supplemental Table 1). Two additional primers, EMSA mut1 and EMSA mut2 (Supplemental Table 1), were used to generate the mutation in the *Coup-TFII*-binding site by PCR. Mouse monoclonal antibody against COUP-TFII was used for the supershift.

ChIP

Human LECs (Lonza) were maintained in culture per the manufacturers' suggestions. ChIP was performed as described previously (Geng et al. 2008). The sheared chromatin was precleared using rabbit anti-IgG antibody (Santa Cruz Biotechnologies). Subsequently, ChIP was carried out with or without the rabbit anti-COUP-TFII antibody. Following the pull-down of the chromatin fragments, real-time PCR was carried out using primers and probes specific for the conserved COUP-TFII-binding

Figure 7. Model of the roles of *Coup-TFII* in the regulation of *Prox1* expression during lymphatic vascular development. *Coup-TFII* alone is not sufficient to induce *Prox1* expression in LECs. Therefore, in this working model, we suggest that *Coup-TFII* cooperates with *Sox18* to initiate *Prox1* expression in LEC progenitors. Once initiated, two mechanisms may maintain *Prox1* expression in differentiating LECs. *Prox1* could be recruited to its own promoter due to its interaction with *Coup-TFII* and subsequently regulate and maintain its own expression. Alternatively, the *Coup-TFII*-*Prox1* complex might activate an as-yet-unknown transcription factor X, which in turn maintains *Prox1* expression.

site (ChIP1–3), the nonconserved COUP-TFII-binding site (ChIP4–6), and the nonspecific control site (ChIP7–9) (Supplemental Table 1). Real-time PCR was carried out according to the manufacturers' instructions (Applied Biosystems).

Luciferase reporter gene assays

Synthetic oligonucleotides containing six consecutive conserved Coup-TFII-binding sites were cloned into the pGL3 basic reporter construct (Promega). Two additional versions of this plasmid were made containing either 4- or 8-nt substitutions in each of the 16-nt repeats. All of the nucleotide sequences are provided in Supplemental Table 1. The generated reporter plasmids (100 ng), Renilla luciferase reporter under TK promoter (1 ng; Promega), and the indicated amount of COUP-TFII expression plasmid CMV6-XL5 (Origene) were mixed together and incubated with Fugene 6 transfection reagent (Roche) according to the manufacturers' instructions. Twenty-four hours prior to transfection, the 293T cells were plated at a concentration of 50×10^3 cells per well into 24-well plates. The DNA–Fugene 6 mix was split equally and added to four wells of the 24-well plates. Thirty-six hours later, the cells were harvested, and the Dual luciferase assay (Promega) was performed according to the manufacturers' instructions. The ratio of firefly to renilla luciferase activities (RLU) was measured, and the average and standard deviation were documented as the fold induction.

TM administration

TM preparation and intraperitoneal injections of pregnant dams were carried out as described previously (Srinivasan et al. 2007). Gavage of pups with TM was also done as described previously (Johnson et al. 2008).

In situ hybridization, immunohistochemistry, Western blotting, detection of LacZ activity, and TUNEL assay

Whole-mount X-gal staining and immunostaining were carried out as described previously (Harvey et al. 2005; Srinivasan et al. 2007). Fluorescent immunohistochemistry and in situ hybridization were performed as described previously (Srinivasan et al. 2007). Western blots were carried out using standard protocols and a monoclonal antibody against COUP-TFII. TUNEL assay was performed as described previously (Geng et al. 2008).

Viral constructs and viral particle generation

Full-length *Prox1* or *avitag-Prox1* cDNAs were cloned into a two-promoter MSCV-fl-sv-Puro retroviral vector containing the LTR promoter and an SV40-Puro selection cassette. Viral particles pseudotyped with VSV-G and PEQ-PAM were generated by transient transfection in 293T cells. Briefly, 293T cells were plated at 2×10^6 cells per 100-mm-diameter tissue culture dish and transfected with the retroviral vector (empty or containing *Prox1* or *avitag-Prox1*) using standard protocols. At 12 h post-transfection, the medium was replaced with fresh DMEM containing 10% FBS, and cells were grown for an additional 24 h. The conditioned medium containing recombinant retroviruses was collected and was filtered through polysulfonic filters (pore size, 0.45 μ m; Corning).

Viral infection and generation of stable cell lines

For retroviral infections, H5V cells were plated at a density of 10^6 cells per 100-mm-diameter tissue culture dish. Eighteen hours later, retrovirus supernatants and 8 mg/mL Polybrene (Sigma)

were applied to the H5V cells and incubated for 12 h. Selection with 1.5 mg/mL puromycin was initiated 12 h after infection. After selection for ~ 10 d, cells were seeded at 1×10^4 cells per 100-mm-diameter tissue culture dish. Individual clones were picked, transferred to 24-well plates, and expanded to generate cells that stably expressed WT-*Prox1* or *avitag-Prox1*.

Immunofluorescence microscopy

Transduced H5V cells and human LECs were fixed on ice in 2% paraformaldehyde for 10 min and subsequently in 100% methanol for 1 min. Cells were washed three times for 5 min each in PBS at room temperature, permeabilized, and blocked in 0.01% Triton X-100, 2% FBS, and 0.5% BSA in PBS for 30 min at room temperature. They were then incubated with the indicated primary antibodies and subsequently with the corresponding secondary antibodies. Slides were mounted in VectaShield mounting medium (Vector Laboratories) and photographed.

Acknowledgments

We thank Drs. S. Tsai and M.-J. Tsai for providing the Coup-TFII floxed mouse strain; Dr. J. Westmoreland for the *Prox1*^{+/flox};R26R mouse strain; Dr. J. Johnson for the *Rbpj* floxed mouse strain; Dr. Y. Lee for help with the design of primers and probes for real-time PCR; Drs. J. Downing, S. Baker, and R. Endersby for providing the GFPcre cDNA cassette; Drs. F. Mathias and P. Koopmann for the *Sox18* in situ probe; Dr. M. Yanagisawa for the *Tie2-Cre* strain; Dr. E. Dejana for the H5V cells; Mr. S. Connell, Dr. L. Zhao, Dr. Y. Ouyang and Dr. J. Peterson for help with confocal imaging; and Dr. A. McArthur for editing of this manuscript. We thank all of the members of our laboratory for their helpful suggestions and discussions. This work was supported by NIH grant R01-HL073402 (to G.O.) and the American Lebanese Syrian Associated Charities (ALSAC).

References

- Bull LN, Roche E, Song EJ, Pedersen J, Knisely AS, van Der Hagen CB, Eiklid K, Aagenaes O, Freimer NB. 2000. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. *Am J Hum Genet* 67: 994–999.
- de Boer J, Williams A, Skavdis G, Harker N, Coles M, Tolaini M, Norton T, Williams K, Roderick K, Potocnik AJ, et al. 2003. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. *Eur J Immunol* 33: 314–325.
- Delorme B, Dahl E, Jarry-Guichard T, Briand JP, Willecke K, Gros D, Theveniau-Ruissy M. 1997. Expression pattern of connexin gene products at the early developmental stages of the mouse cardiovascular system. *Circ Res* 81: 423–437.
- Francois M, Caprini A, Hosking B, Orsenigo F, Wilhelm D, Browne C, Paavonen K, Karnezis T, Shayan R, Downes M, et al. 2008. *Sox18* induces development of the lymphatic vasculature in mice. *Nature* 456: 643–647.
- Fruhworth M, Janecke AR, Muller T, Carlton VE, Kronenberg F, Offner F, Knisely AS, Geleff S, Song EJ, Simma B, et al. 2003. Evidence for genetic heterogeneity in lymphedema-cholestasis syndrome. *J Pediatr* 142: 441–447.
- Geng X, Speirs C, Lagutin O, Inbal A, Liu W, Solnica-Krezel L, Jeong Y, Epstein DJ, Oliver G. 2008. Haploinsufficiency of *Six3* fails to activate Sonic hedgehog expression in the ventral forebrain and causes holoprosencephaly. *Dev Cell* 15: 236–247.
- Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, Sleeman MW, Oliver G. 2005. Lymphatic vascular

- defects promoted by *Prox1* haploinsufficiency cause adult-onset obesity. *Nat Genet* **37**: 1072–1081.
- Jeong Y, Leskow FC, El-Jaick K, Roessler E, Muenke M, Yocum A, Dubourg C, Li X, Geng X, Oliver G, et al. 2008. Regulation of a remote *Shh* forebrain enhancer by the *Six3* homeoprotein. *Nat Genet* **40**: 1348–1353.
- Johnson NC, Dillard ME, Baluk P, McDonald DM, Harvey NL, Frase SL, Oliver G. 2008. Lymphatic endothelial cell identity is reversible and its maintenance requires *Prox1* activity. *Genes & Dev* **22**: 3282–3291.
- Kato H, Taniguchi Y, Kurooka H, Minoguchi S, Sakai T, Nomura-Okazaki S, Tamura K, Honjo T. 1997. Involvement of RBP-J in biological functions of mouse *Notch1* and its derivatives. *Development* **124**: 4133–4141.
- Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. 2001. Tie2-Cre transgenic mice: A new model for endothelial cell-lineage analysis in vivo. *Dev Biol* **230**: 230–242.
- Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T. 2004. Haploinsufficient lethality and formation of arteriovenous malformations in *Notch* pathway mutants. *Genes & Dev* **18**: 2469–2473.
- Lee S, Kang J, Yoo J, Ganesan SK, Cook SC, Aguilar B, Ramu S, Lee J, Hong YK. 2009. *Prox1* physically and functionally interacts with COUP-TFII to specify lymphatic endothelial cell fate. *Blood* **113**: 1856–1859.
- Li L, Xie X, Qin J, Jeha GS, Saha PK, Yan J, Haueter CM, Chan L, Tsai SY, Tsai MJ. 2009. The nuclear orphan receptor COUP-TFII plays an essential role in adipogenesis, glucose homeostasis, and energy metabolism. *Cell Metab* **9**: 77–87.
- Liu YW, Gao W, Teh HL, Tan JH, Chan WK. 2003. *Prox1* is a novel coregulator of *Ff1b* and is involved in the embryonic development of the zebra fish interrenal primordium. *Mol Cell Biol* **23**: 7243–7255.
- Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, Reuter J, Chekmenev D, Krull M, Hornischer K, et al. 2006. TRANSFAC and its module TRANSCOMP: Transcriptional gene regulation in eukaryotes. *Nucleic Acids Res* **34**: D108–D110. doi: 10.1093/nar/gkj143.
- Oliver G, Alitalo K. 2005. The lymphatic vasculature: Recent progress and paradigms. *Annu Rev Cell Dev Biol* **21**: 457–483.
- Oliver G, Srinivasan RS. 2008. Lymphatic vasculature development: Current concepts. *Ann N Y Acad Sci* **1131**: 75–81.
- Pennisi D, Gardner J, Chambers D, Hosking B, Peters J, Muscat G, Abbott C, Koopman P. 2000. Mutations in *Sox18* underlie cardiovascular and hair follicle defects in ragged mice. *Nat Genet* **24**: 434–437.
- Qin J, Gao DM, Jiang QF, Zhou Q, Kong YY, Wang Y, Xie YH. 2004. Prospero-related homeobox (*Prox1*) is a corepressor of human liver receptor homolog-1 and suppresses the transcription of the cholesterol 7- α -hydroxylase gene. *Mol Endocrinol* **18**: 2424–2439.
- Schatz PJ. 1993. Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: A 13 residue consensus peptide specifies biotinylation in *Escherichia coli*. *Biotechnology* **11**: 1138–1143.
- Scholle MD, Collart FR, Kay BK. 2004. In vivo biotinylated proteins as targets for phage-display selection experiments. *Protein Expr Purif* **37**: 243–252.
- Soriano P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat Genet* **21**: 70–71.
- Srinivasan RS, Dillard ME, Lagutin OV, Lin FJ, Tsai S, Tsai MJ, Samokhvalov IM, Oliver G. 2007. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. *Genes & Dev* **21**: 2422–2432.
- Steffensen KR, Holter E, Bavner A, Nilsson M, Peltto-Huikko M, Tomarev S, Treuter E. 2004. Functional conservation of interactions between a homeodomain cofactor and a mammalian FTZ-F1 homologue. *EMBO Rep* **5**: 613–619.
- Takamoto N, You LR, Moses K, Chiang C, Zimmer WE, Schwartz RJ, DeMayo FJ, Tsai MJ, Tsai SY. 2005. COUP-TFII is essential for radial and anteroposterior patterning of the stomach. *Development* **132**: 2179–2189.
- Tanigaki K, Han H, Yamamoto N, Tashiro K, Ikegawa M, Kuroda K, Suzuki A, Nakano T, Honjo T. 2002. Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. *Nat Immunol* **3**: 443–450.
- Thomas-Chollier M, Sand O, Turatsinze JV, Janky R, Defrance M, Vervisch E, Brohee S, van Helden J. 2008. RSAT: Regulatory sequence analysis tools. *Nucleic Acids Res* **36**: W119–W127. doi: 10.1093/nar/gkn304.
- Tripodi M, Filosa A, Armentano M, Studer M. 2004. The COUP-TF nuclear receptors regulate cell migration in the mammalian basal forebrain. *Development* **131**: 6119–6129.
- Wang L, Zhu J, Shan S, Qin Y, Kong Y, Liu J, Wang Y, Xie Y. 2008. Repression of interferon- γ expression in T cells by Prospero-related homeobox protein. *Cell Res* **18**: 911–920.
- Wigle JT, Oliver G. 1999. *Prox1* function is required for the development of the murine lymphatic system. *Cell* **98**: 769–778.
- Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, Jackson DG, Oliver G. 2002. An essential role for *Prox1* in the induction of the lymphatic endothelial cell phenotype. *EMBO J* **21**: 1505–1513.
- Yamazaki T, Yoshimatsu Y, Morishita Y, Miyazono K, Watabe T. 2009. COUP-TFII regulates the functions of *Prox1* in lymphatic endothelial cells through direct interaction. *Genes Cells* **14**: 425–434.
- You LR, Lin FJ, Lee CT, DeMayo FJ, Tsai MJ, Tsai SY. 2005. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. *Nature* **435**: 98–104.

The nuclear hormone receptor Coup-TFI is required for the initiation and early maintenance of *Prox1* expression in lymphatic endothelial cells

R. Sathish Srinivasan, Xin Geng, Ying Yang, et al.

Genes Dev. 2010, **24**:

Access the most recent version at doi:[10.1101/gad.1859310](https://doi.org/10.1101/gad.1859310)

Supplemental Material

<http://genesdev.cshlp.org/content/suppl/2010/03/31/24.7.696.DC1>

References

This article cites 34 articles, 11 of which can be accessed free at:
<http://genesdev.cshlp.org/content/24/7/696.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).